Advanced melanoma that has spread widely through the body follows a trajectory shaped by which organs are involved, how quickly the disease progresses, and how the body responds to both the cancer and its treatments. The final weeks and days typically bring a combination of deepening fatigue, loss of appetite, neurological changes, and organ-specific symptoms that reflect where the melanoma has taken hold. Understanding what to expect can help patients and families prepare, make informed decisions about comfort care, and recognize when the body is actively dying.
Where Melanoma Goes When It Spreads
Melanoma in its late stages has an unusually broad reach compared to many cancers. It can seed itself in the lungs, liver, brain, bones, gastrointestinal tract, and even the spleen and subcutaneous tissues, sometimes simultaneously across multiple organ systems.1PubMed Central. Metastatic multifocal melanoma of multiple organ systems: A case report The specific combination of organs affected shapes the symptom picture in the final stages. Someone whose melanoma has primarily colonized the brain will have a very different experience from someone whose liver is the dominant site of disease. Uveal melanoma, a subtype arising in the eye, tends to spread heavily to the liver, and these patients often face liver-dominant decline.2PubMed Central. Phase I trial of locoregional administration of autologous tumor-infiltrating lymphocytes in patients with uveal melanoma and liver metastases (the HAITILS trial)
This multifocal spread is part of what makes end-stage melanoma so unpredictable. A patient might be coping with bone pain and mild fatigue, then develop sudden neurological symptoms when previously undetected brain lesions grow or bleed. Families often describe feeling blindsided by a rapid shift, and that experience is consistent with how melanoma behaves: it can simmer in one organ while quietly establishing itself in others.
Brain Metastases and Neurological Decline
The brain is one of melanoma’s most common and feared destinations. A large study of melanoma brain metastases found that roughly 39% of patients had no symptoms at the time their brain lesions were discovered, while about a third presented with headache, confusion, or other mental status changes. Around 20% had focal symptoms like weakness or numbness in a limb, and about 8% had seizures as their first sign.3PubMed Central. Melanoma Brain Metastasis Presentation, Treatment and Outcomes in the Age of Targeted- and Immuno-therapies Headaches were especially common when the tumor sat in the cerebellum or brainstem area, while seizures occurred more with frontal and parietal lobe involvement.
As brain disease progresses in the final stages, these symptoms intensify. Patients may develop increasing confusion, personality changes, difficulty speaking, or progressive loss of motor control. The larger the lesions grow, the more swelling builds inside the skull, and the more function is lost. Steroids like dexamethasone are commonly used to reduce brain swelling and temporarily improve symptoms.4PubMed Central. Bevacizumab as a steroid-sparing agent during immunotherapy for melanoma brain metastases: A case series But over time, steroids lose their effectiveness, and the neurological decline deepens.
A particularly devastating development is leptomeningeal disease, where melanoma cells infiltrate the membranes surrounding the brain and spinal cord and seed into the cerebrospinal fluid. This complication affects up to 15% of melanoma patients who already have brain involvement, and it carries a median survival measured in weeks to a few months even with aggressive treatment.5PubMed Central. Outcomes and prognostic factors in melanoma patients with leptomeningeal disease: a retrospective cohort study Death from leptomeningeal disease typically occurs through progressive neurological dysfunction: worsening confusion, cranial nerve problems affecting vision and swallowing, and eventually coma.6PubMed Central. Leptomeningeal Disease (LMD) in Patients with Melanoma Metastases
Liver Failure and Organ Decline
When melanoma infiltrates the liver heavily, it can cause acute liver failure that progresses with alarming speed. The mechanism involves tumor cells flooding the tiny blood vessels (sinusoids) within the liver, choking off blood flow and killing liver cells. Patients often present with nonspecific symptoms at first: pain in the upper right abdomen, fatigue, nausea, and loss of appetite. Bloodwork may show moderately elevated liver enzymes and a sharply rising LDH level, which signals extensive tissue damage.7PubMed Central. Metastatic melanoma: an unexpected cause of acute liver failure
The liver may enlarge dramatically without showing the distinct nodules typical of other cancers, making it difficult to detect on imaging until the disease is advanced. Once liver function fails, patients develop jaundice (yellowing of the skin and eyes), fluid accumulation in the abdomen, worsening confusion from toxin buildup in the blood, and eventually bleeding problems because the liver can no longer produce clotting factors. The prognosis once acute liver failure sets in is measured in days to weeks. In some cases, the diagnosis is only confirmed after death because the patient is too unstable for a liver biopsy.7PubMed Central. Metastatic melanoma: an unexpected cause of acute liver failure
Lung metastases, which are common in advanced melanoma, contribute to end-stage decline through progressive shortness of breath, coughing, and eventually respiratory failure. When the lungs, liver, or both are heavily involved, patients often experience a cascading failure where one organ’s decline accelerates the others.
Bone Pain and Skeletal Complications
About 17% of patients with advanced melanoma develop bone metastases, and these bring a distinctive set of problems. In a study tracking skeletal complications, roughly two-thirds of patients with bone metastases experienced at least one major event: radiation therapy for bone pain, dangerously high blood calcium levels, bone fractures, or spinal cord compression.8Journal of Bone Oncology. Complications of bone metastases from malignant melanoma Median survival from the time bone metastases were identified was about 17 weeks, and when high calcium levels developed, survival dropped to a median of roughly 5 to 6 weeks.
Bone pain from melanoma metastases can be severe and relentless, often worse at night and with movement. When cancer weakens the spine, there is a risk of spinal cord compression, which causes sudden worsening back pain, weakness or numbness in the legs, and loss of bladder or bowel control. This is an emergency even in the palliative setting because untreated compression leads to permanent paralysis. Pathological fractures, where a bone breaks through normal activity because tumor has hollowed it out, are another painful complication.9PubMed Central. Malignant melanoma with indiscoverable skin manifestations presenting with paresis and refractory hypercalcemia: A case report
Hypercalcemia from bone destruction deserves special mention because its symptoms are easy to mistake for simple disease progression. High blood calcium causes confusion, extreme thirst, constipation, nausea, and drowsiness. Families and even clinicians may attribute these to “the cancer getting worse” without checking calcium levels, but treating high calcium with fluids and medications can sometimes meaningfully improve comfort and alertness, at least temporarily.
Cachexia and Physical Wasting
The progressive weight loss and muscle wasting seen in advanced melanoma is a condition called cachexia. It is driven not just by reduced appetite but by the cancer itself reprogramming the body’s metabolism: ramping up inflammation, breaking down muscle protein, and depleting fat stores.10PubMed Central. Cancer cachexia: molecular mechanisms and treatment strategies This is why patients often continue losing weight and muscle even when they try to eat. Cachexia is not starvation in the usual sense. Providing more calories does not reverse it because the underlying metabolic derangement persists.
Research in animal models of melanoma-associated cachexia has shown that wasting affects different organs at different rates. Skeletal muscles, including the diaphragm (the main breathing muscle), lose mass significantly. Heart weight also declines. The brain, by contrast, is relatively spared in terms of tissue loss, though its function may still be affected by the systemic illness.11Cell Reports. Progressive development of melanoma-induced cachexia differentially impacts organ systems in mice This pattern helps explain why patients become so profoundly weak and breathless even when their lungs themselves are not the primary site of disease: the muscles responsible for breathing are wasting away.
For families, watching cachexia unfold is often one of the hardest parts. The instinct to push food and drink is strong, but it is worth knowing that forcing intake typically causes more distress than comfort in late-stage disease. At some point, the body simply cannot process nutrition effectively, and the focus appropriately shifts to comfort measures.
Gastrointestinal Involvement
Melanoma is one of the cancers most likely to spread to the gastrointestinal tract. When it does, it can produce abdominal pain, difficulty swallowing, constipation, bowel obstruction, or bleeding that shows up as dark stools or vomiting blood.12Mayo Clinic Proceedings. Metastatic Malignant Melanoma of the Gastrointestinal Tract: Report of 2 Cases and Review of the Literature These symptoms are often indistinguishable from other GI problems, which can delay recognition.
In the final stages, bowel obstruction is a particularly distressing complication. It can cause severe cramping pain, vomiting, and bloating. Surgery to relieve an obstruction is sometimes performed even in palliative settings if it would meaningfully improve comfort, but in very advanced disease, the decision often shifts toward managing symptoms with medications rather than operating. Bleeding from GI metastases can also be difficult to control and may contribute to worsening anemia, fatigue, and overall decline.
Skin and Wound Complications
Because melanoma begins in the skin, advanced disease sometimes produces visible, external manifestations that are uniquely challenging. Tumors can grow through the skin surface to form what are called fungating wounds, which are open, often foul-smelling lesions that bleed easily. One case involved a melanoma mass on the back that reached 10 centimeters in size, caused bleeding and significant odor, and required palliative surgery to manage symptoms.13Premier Journal of Case Reports. Giant Nodular Stage IV Melanoma Presenting as a Fungating Upper Back Mass: Palliative Surgical Management and Reconstruction in a Multimorbid Patient: A Case Report
Managing these wounds is primarily about quality of life rather than cure. The goals include controlling odor (often with topical treatments or specialized dressings), minimizing bleeding, and preventing infection. These wounds are emotionally difficult for both patients and caregivers because they are a constant, visible reminder of the disease.14PubMed Central. Management of malignant cutaneous wounds in oncologic patients Palliative wound care teams, where available, can make a significant difference in comfort.
Delirium and Restlessness
Delirium affects the vast majority of cancer patients in the days before death. It can take a quiet form, where the person becomes withdrawn and confused, or an agitated form, where they become restless, pick at bedding, call out, or seem frightened by things others cannot see. End-of-life delirium is deeply distressing for families, who may wonder if their loved one is suffering or aware of their distress.15PubMed Central. Pharmacologic Management of End-of-Life Delirium: Translating Evidence into Practice
In melanoma specifically, delirium may be compounded by brain metastases, liver failure releasing toxins into the blood, high calcium levels, medications, or simply the cumulative burden of systemic illness. Sometimes a reversible cause can be identified and treated, temporarily restoring clarity. More often in the final days, delirium is irreversible and the goal becomes keeping the patient calm and comfortable with medications like antipsychotics or sedatives.
Physical Signs in the Final Days
In the last 72 hours of life, a set of recognizable physical changes often signals that death is very near. A prospective study of advanced cancer patients identified eight signs that strongly predicted death within three days. These included pupils that no longer reacted to light, decreased response to voice or visual cues, inability to close the eyelids fully, drooping of the facial muscles on one side, a characteristic backward tilting of the neck, grunting sounds with breathing, and upper GI bleeding.16PubMed Central. Bedside clinical signs associated with impending death in patients with advanced cancer: Preliminary findings of a prospective longitudinal cohort study These signs were highly specific, meaning that when they appeared, death within days was very likely.
Other common changes in the final hours include a distinctive breathing pattern with long pauses between breaths, mottling of the skin (a lace-like purplish discoloration starting in the knees and feet), cool extremities, and a sharp drop in urine output. The person may be completely unresponsive but still have some degree of hearing intact, which is why hospice teams encourage families to continue speaking gently and expressing what they need to say.
Pain Management and Comfort Medications
One of the greatest fears for both patients and families is uncontrolled pain or suffering in the final stages. The evidence on this front is reassuring in one important respect: opioids and sedatives used for symptom control in the last days of life do not shorten survival. A study examining high-dose opioids and sedatives in terminally ill cancer patients found no significant difference in survival between those who received higher doses and those who received lower ones. The researchers concluded that these medications are safe when started at appropriate doses and increased gradually to match symptoms.17Journal of Pain and Symptom Management. Effects of High Dose Opioids and Sedatives on Survival in Terminally Ill Cancer Patients
This finding matters because families sometimes worry that increasing morphine or starting sedation will “hasten death.” The data suggests otherwise: adequate pain and symptom control allows the body to rest and reduces the physiological stress of suffering. In the last days, when a patient can no longer swallow pills, medications can be given through patches, under the tongue, or through a small needle placed under the skin. Hospice teams are experienced at managing this transition and adjusting doses to keep the patient comfortable.
For agitated delirium that does not respond to standard medications, palliative sedation may be offered. This involves using sedatives to lower consciousness to the point where the patient is no longer aware of their distress. It is a last resort reserved for truly refractory suffering, and it is ethically and medically distinct from euthanasia.
When Treatments Stop Working
One of the most difficult transitions in the melanoma journey comes when active treatments, whether immunotherapy, targeted therapy, or both, stop controlling the disease. Modern melanoma treatments can produce remarkable responses, but not all of them last. Among patients treated with targeted therapy (BRAF inhibitors with or without MEK inhibitors) who achieved a complete response, more than half eventually relapsed while still on treatment.18PubMed Central. Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma—A Retrospective Multicenter ADOReg Study
Immunotherapy has its own complications. About 41% of patients in one study developed permanent immune-related side effects, most commonly involving the hormonal system or skin, with roughly 12% experiencing severe toxicities like adrenal insufficiency or inflammation of the heart or spinal cord.19PubMed Central. Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients These treatment side effects can themselves complicate the final stages of disease. A patient who has developed adrenal insufficiency from immunotherapy, for example, needs ongoing steroid replacement even after stopping cancer treatment, and missing doses can cause a dangerous crisis.
There is also the troubling phenomenon of hyperprogression, where disease accelerates dramatically after starting immunotherapy rather than responding or simply continuing at its previous pace. In one study, more than half of patients whose melanoma progressed on immunotherapy showed this hyperprogressive pattern, and it was associated with substantially worse survival.20PubMed Central. PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors Recognizing when treatment is no longer helping, and may even be causing harm, is a critical part of end-of-life planning.
Hospice Timing
Research consistently suggests that earlier hospice enrollment benefits melanoma patients. A study of patients with metastatic melanoma found that those enrolled in hospice for four or more days had a median survival of about 10 months, compared with roughly 6 months for those who received no hospice care or enrolled for just one to three days. The longer-hospice group also incurred about half the end-of-life costs.21PubMed. Survival and cost-effectiveness of hospice care for metastatic melanoma patients This does not necessarily mean hospice itself extends life, since healthier patients may be more likely to enroll earlier, but the pattern reinforces that hospice is not about “giving up.” Earlier access to palliative care specialists tends to increase both the likelihood of hospice enrollment and the duration of care received.22Journal of Pain and Symptom Management. Variations in Hospice Utilization and Length of Stay for Medicare Patients With Melanoma
For families, hospice provides something that is hard to quantify: expertise in what is happening and what comes next. Hospice nurses can recognize the signs of approaching death that feel terrifying to unprepared family members, and they can explain in real time what each change means and what it does not mean. They can adjust medications rapidly, provide emotional support, and help families understand that changes in breathing, periods of unresponsiveness, and refusal of food are not signs of suffering but of the body’s natural process of shutting down. The question of when to transition to hospice is often framed as “when is it too early,” but in practice, the more common problem is waiting too long.